Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | UGCG | Q16739 | 5/20 | 0.50 |
| ▸ | GBA2 | Q9HCG7 | 5/20 | 0.50 |
| ▸ | GBA1 | P04062 | 4/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | LCT | P09848 | 2/20 | 0.43 |
| ▸ | SI | P14410 | 2/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL518615 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL1246210 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL8482826 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL6212152 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL9684333 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL25208054 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL97795 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL814418 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL1007794 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL22906771 | 0.98 | L3MBTL1 (0.53) | L3MBTL1TDP1TSHRUGCGGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198382-A1 | Oxiran carboxylic acids for the treatment of diabetes | HORST P.O. WOLF (DE) | 2002-12-26 | — | — | US | claimed |
| US-6013666-A | ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION | Jew, Sang Sup (KR) | 2000-01-11 | — | — | US | claimed |
| WO-1998000422-A1 | OXIRANE CARBOXYLIC ACID DERIVATIVE AND ITS MANUFACTURING METHOD | JEW SANG SUP (KR) | 1998-01-08 | — | — | WO | claimed |
| US-20260132133-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4739652-A1 | LIPIDS AND COMPOSITIONS THEREOF | Kernal Biologics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | KERNAL BIOLOGICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4727915-A1 | AMIDE CONTAINING LIPIDS | Acuitas Therapeutics, Inc. (CA) | 2026-04-22 | — | — | EP | disclosed |
| US-12441708-B2 | Cereblon ligands and bifunctional compounds comprising the same | ARVINAS OPERATIONS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250313547-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS INC (US) | 2025-10-09 | — | — | US | disclosed |
| WO-2025134071-A1 | MALIC AND GLUTARIC ACID BASED IONIZABLE LIPIDS | SANOFI (FR) | 2025-06-26 | — | — | WO | disclosed |
| EP-4511128-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-0180188-B1 | A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| US-5066658-A | Enzyme Inhibitors; Bronchodilators; Antiinflammatory Agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-11-19 | — | — | US | disclosed |
| US-4988680-A | Phosphorylase inhibitors, immuno suppressants, parasiticides, antileukemia agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-01-29 | — | — | US | disclosed |
| EP-0228222-B1 | PESTICIDAL DIHALOVINYLALKENYLAMIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-05-23 | — | — | EP | disclosed |
| CN-1037342-A | Phosphonoalkylpurinederivatives derivatives | MERRELL DOW PHARMA (US) | 1989-11-22 | — | — | CN | disclosed |
| EP-0338168-A1 | Phosphonoalkylpurine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-10-25 | — | — | EP | disclosed |
| EP-0338887-A1 | Phosphonoalkylpurine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-10-25 | — | — | EP | disclosed |
| EP-0228222-A2 | Pesticidal dihalovinylalkenylamides | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-07-08 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313547-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | L3MBTL1 1152/4885TDP1 2849/4885TSHR 3772/4885 |
| US-20020198382-A1 | Oxiran carboxylic acids for the treatment of diabetes | GPR119, SLC5A2, SLC2A4 | L3MBTL1 4472/4885TDP1 4817/4885TSHR 999/4885 |
| US-20260132133-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KRAS, HRAS, BCL6 | L3MBTL1 574/4885TDP1 2369/4885TSHR 371/4885 |
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | LIPC, LIPA, NPC1L1 | L3MBTL1 295/4885TDP1 1579/4885TSHR 1603/4885 |
| US-12441708-B2 | Cereblon ligands and bifunctional compounds comprising the same | CRBN, CBL, MDM2 | L3MBTL1 1152/4885TDP1 2849/4885TSHR 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.